4737 Stock Overview
Designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, Egypt, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Bionime Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$65.50 |
| 52 Week High | NT$76.60 |
| 52 Week Low | NT$60.80 |
| Beta | 0.60 |
| 1 Month Change | -6.43% |
| 3 Month Change | -7.49% |
| 1 Year Change | -12.32% |
| 3 Year Change | -13.93% |
| 5 Year Change | -17.92% |
| Change since IPO | -2.64% |
Recent News & Updates
Recent updates
Bionime (TWSE:4737) Is Reducing Its Dividend To NT$2
Jul 22
Bionime (TWSE:4737) Will Pay A Smaller Dividend Than Last Year
Jul 01These Return Metrics Don't Make Bionime (TPE:4737) Look Too Strong
Apr 29Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?
Mar 23Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?
Mar 05Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?
Feb 15
Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet
Feb 01How Has Bionime (TPE:4737) Allocated Its Capital?
Jan 19A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE
Jan 06A Look At The Fair Value Of Bionime Corporation (TPE:4737)
Dec 22Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend
Dec 09Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment
Nov 24Shareholder Returns
| 4737 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | -2.8% | -2.0% | -2.1% |
| 1Y | -12.3% | -5.9% | 25.6% |
Return vs Industry: 4737 underperformed the TW Medical Equipment industry which returned -5.9% over the past year.
Return vs Market: 4737 underperformed the TW Market which returned 25.6% over the past year.
Price Volatility
| 4737 volatility | |
|---|---|
| 4737 Average Weekly Movement | 2.6% |
| Medical Equipment Industry Average Movement | 3.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4737 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4737's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Roy Huang | www.bionime.com |
Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, Egypt, and internationally. The company offers blood glucose monitors and self-monitors, as well as accessories, such as test strips and lancing devices for hospital and clinical use. It is also involved in the provision of biotechnology services; examining of pharmaceuticals; and selling of precision instruments.
Bionime Corporation Fundamentals Summary
| 4737 fundamental statistics | |
|---|---|
| Market cap | NT$4.00b |
| Earnings (TTM) | -NT$83.24m |
| Revenue (TTM) | NT$1.92b |
2.1x
P/S Ratio-48.0x
P/E RatioIs 4737 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4737 income statement (TTM) | |
|---|---|
| Revenue | NT$1.92b |
| Cost of Revenue | NT$1.12b |
| Gross Profit | NT$796.58m |
| Other Expenses | NT$879.82m |
| Earnings | -NT$83.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.36 |
| Gross Margin | 41.46% |
| Net Profit Margin | -4.33% |
| Debt/Equity Ratio | 158.8% |
How did 4737 perform over the long term?
See historical performance and comparisonDividends
3.1%
Current Dividend Yield-146%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:01 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bionime Corporation is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ryan Liu | IBTS Investment Consulting Co., Ltd. |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
| Hsiu Chi Lin | Masterlink Securities Corp. |